Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures.
3D cell culture
DNA damage
combinational treatment
gold nanoparticles
histone deacetylase inhibitor
radiosensitization
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
16 Jan 2020
16 Jan 2020
Historique:
received:
17
12
2019
revised:
04
01
2020
accepted:
13
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
epublish
Résumé
Radiosensitizing agents are capable of augmenting the damage of ionizing radiation preferentially on cancer cells, thereby increasing the potency and the specificity of radiotherapy. Metal-based nanoparticles have recently gathered ground in radio-enhancement applications, owing to their exceptional competence in amplifying the cell-killing effects of irradiation. Our aim was to examine the radiosensitizing performance of gold nanoparticles (AuNPs) and the chromatin-modifying histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) alone and in combination. We observed that the colony-forming capability of cancer cells decreased significantly and the DNA damage, detected by γH2AX immunostaining, was substantially greater after combinational treatments than upon individual drug exposures followed by irradiation. Synergistic radiosensitizing effects of AuNPs and SAHA were proven on various cell lines, including radioresistant A549 and DU-145 cancer cells. 3D cultures often manifest radio- and drug-resistance, nevertheless, AuNPs in combination with SAHA could effectively enhance the potency of irradiation as the number of viable cells decreased significantly when spheroids received AuNP + SAHA prior to radiotherapy. Our results imply that a relaxed chromatin structure induced by SAHA renders the DNA of cancerous cells more susceptible to the damaging effects of irradiation-triggered, AuNP-released reactive electrons. This feature of AuNPs should be exploited in multimodal treatment approaches.
Identifiants
pubmed: 31963267
pii: nano10010158
doi: 10.3390/nano10010158
pmc: PMC7023030
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hungarian Government and the European Union
ID : GINOP-2.3.2-15-2016-00035
Organisme : Hungarian Government and the European Union
ID : GINOP-2.3.2-15-2016-00038
Organisme : New National Excellence Program of the Ministry for Innovation and Technology
ID : UNKP-19-4-SZTE-14
Organisme : János Bolyai Research Scholarship of the Hungarian Academy of Sciences
ID : BO/00878/19/8
Organisme : Szeged Scientists Academy under the sponsorship of the Hungarian Ministry of Human Capacities
ID : EMMI: 13725-2/2018/INTFIN
Références
Nat Rev Cancer. 2006 Jan;6(1):38-51
pubmed: 16397526
Exp Cell Res. 2007 Aug 15;313(14):3066-75
pubmed: 17524393
Cancer Res. 2010 May 15;70(10):3925-34
pubmed: 20442295
J Cancer. 2018 Oct 18;9(22):4128-4138
pubmed: 30519312
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Strahlenther Onkol. 2003 May;179(5):337-44
pubmed: 12740661
Int J Mol Sci. 2016 Sep 13;17(9):
pubmed: 27649147
Theranostics. 2018 Feb 12;8(7):1824-1849
pubmed: 29556359
Nat Rev Drug Discov. 2002 Apr;1(4):287-99
pubmed: 12120280
Med Phys. 1990 Jan-Feb;17(1):10-6
pubmed: 2106608
Oncogene. 2007 Jun 7;26(27):3963-71
pubmed: 17213813
Lancet Oncol. 2005 Jul;6(7):520-8
pubmed: 15992701
J Cell Physiol. 2015 Jan;230(1):16-26
pubmed: 24912145
ACS Nano. 2016 Dec 27;10(12):10631-10635
pubmed: 28024339
Clin Cancer Res. 2009 May 1;15(9):3163-71
pubmed: 19383825
Med Phys. 1995 Jun;22(6):767-73
pubmed: 7565365
Med Phys. 1990 Mar-Apr;17(2):212-26
pubmed: 2110283
Colloids Surf B Biointerfaces. 2016 Oct 1;146:670-7
pubmed: 27434153
Adv Drug Deliv Rev. 2017 Jan 15;109:84-101
pubmed: 26712711
Immunol Cell Biol. 2012 Jan;90(1):85-94
pubmed: 22124371
N Engl J Med. 1998 Jul 2;339(1):21-6
pubmed: 9647875
Nanotechnology. 2010 Feb 26;21(8):85103
pubmed: 20101074
Jpn J Cancer Res. 1998 Mar;89(3):307-14
pubmed: 9600125
Nat Rev Cancer. 2001 Dec;1(3):194-202
pubmed: 11902574
Mol Cell. 2004 Mar 12;13(5):627-38
pubmed: 15023334
Radiat Res. 2017 Aug;188(2):123-143
pubmed: 28557630
Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914
pubmed: 11704310
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12378-82
pubmed: 7528920
Cancer Treat Res. 2015;166:293-322
pubmed: 25895874
Cancer Biol Ther. 2009 May;8(9):823-31
pubmed: 19270532
Nat Rev Cancer. 2004 Oct;4(10):793-805
pubmed: 15510160
J Control Release. 2011 Oct 30;155(2):237-47
pubmed: 21497176
Radiother Oncol. 2011 Jun;99(3):271-8
pubmed: 21704412
Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):781-96
pubmed: 7591884
Chem Rev. 2015 Oct 14;115(19):10410-88
pubmed: 26293344
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
Arch Pharm Res. 2015 Jun;38(6):933-49
pubmed: 25653088
Mol Cancer Res. 2012 Aug;10(8):1052-64
pubmed: 22729783
J Natl Cancer Inst. 2013 Feb 20;105(4):256-65
pubmed: 23291374
ACS Nano. 2016 Feb 23;10(2):2536-48
pubmed: 26815933
Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1878-1890
pubmed: 30262435
Clin Cancer Res. 2005 Jul 1;11(13):4912-22
pubmed: 16000590
Nat Rev Cancer. 2004 Sep;4(9):737-47
pubmed: 15343280
Nanomedicine. 2011 Oct;7(5):580-7
pubmed: 21333757
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):397-417
pubmed: 17478086
Eur J Cancer. 2010 Sep;46(13):2422-31
pubmed: 20619634
ACS Nano. 2016 Dec 27;10(12):10636-10651
pubmed: 27758098
J Colloid Interface Sci. 2013 Mar 15;394:263-8
pubmed: 23332939
Int J Radiat Biol. 2001 Oct;77(10):1033-42
pubmed: 11682008
Theranostics. 2016 Jun 20;6(10):1651-71
pubmed: 27446499
Radiat Oncol J. 2016 Sep;34(3):230-238
pubmed: 27730800
Blood. 1999 Mar 1;93(5):1658-67
pubmed: 10029595
Pharmaceutics. 2018 Oct 18;10(4):
pubmed: 30340364
Int J Mol Sci. 2018 Feb 07;19(2):
pubmed: 29414878
Biol Pharm Bull. 2019;42(1):66-72
pubmed: 30606990
Front Pharmacol. 2018 Mar 22;9:245
pubmed: 29623040
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Int J Radiat Biol. 2000 Oct;76(10):1357-64
pubmed: 11057744
Mol Oncol. 2012 Dec;6(6):579-89
pubmed: 22963873
Oncogene. 2000 Sep 7;19(38):4319-27
pubmed: 10980607
J Biol Chem. 2005 Mar 25;280(12):11528-34
pubmed: 15649887
Prostate. 2019 Sep;79(12):1386-1398
pubmed: 31334877
Lancet Oncol. 2006 Oct;7(10):848-58
pubmed: 17012047
Science. 2005 Jan 14;307(5707):269-73
pubmed: 15653507
Nat Rev Drug Discov. 2013 Jul;12(7):526-42
pubmed: 23812271
Biochim Biophys Acta. 2016 Oct;1864(10):1372-401
pubmed: 27296530
ACS Appl Mater Interfaces. 2017 Apr 19;9(15):13037-13048
pubmed: 28338323
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44
pubmed: 20679231
Radiat Res. 2010 Jun;173(6):719-28
pubmed: 20518651
Radiat Oncol. 2019 Apr 15;14(1):64
pubmed: 30987655
Invest New Drugs. 2012 Feb;30(1):200-11
pubmed: 20931262
Chem Soc Rev. 2011 Jan;40(1):44-56
pubmed: 20818451
Future Med Chem. 2012 Mar;4(4):505-24
pubmed: 22416777
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Rev Cancer. 2011 Apr;11(4):239-53
pubmed: 21430696
J Clin Oncol. 2006 Jun 20;24(18):2786-92
pubmed: 16782917
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
J Radiat Res. 2011;52(5):539-44
pubmed: 21881296